Details

Autor(en) / Beteiligte

• Fätkenheuer, Gerd
• Nelson, Mark
• Lazzarin, Adriano
• Konourina, Irina
• Hoepelman, Andy I.M
• Lampiris, Harry
• Hirschel, Bernard
• Tebas, Pablo
• Raffi, François
• Trottier, Benoit
• Bellos, Nicholaos
• Saag, Michael
• Cooper, David A
• Westby, Mike
• Tawadrous, Margaret
• Sullivan, John F
• Ridgway, Caroline
• Dunne, Michael W
• Felstead, Steve
• Mayer, Howard
• van der Ryst, Elna

Titel

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Ist Teil von

• The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48 weeks. These subgroups include patients with a low baseline CD4 cell count and a high HIV viral load at screening and those receiving no active background antiretroviral agents. In patients in whom maraviroc failed, the CXCR4-using virus was often present at failure. In key subgroups of HIV-infected patients, a consistent treatment benefit of maraviroc over placebo was seen at 48 weeks. These subgroups include patients with a low baseline CD4 cell count and a high HIV viral load at screening and those receiving no active background antiretroviral agents. The CC chemokine receptor 5 (CCR5) antagonist maraviroc has shown potent antiviral activity in vitro and in vivo against the R5 human immunodeficiency virus type 1 (HIV-1). 1 , 2 As reported by Gulick et al. 3 elsewhere in this issue, treatment with maraviroc plus optimized background therapy was associated with significantly greater virologic and immunologic efficacy and had a similar safety profile, as compared with placebo plus optimized background therapy, in the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies at 48 weeks. Subgroup analyses of data from recent trials evaluating new drugs in patients . . .